MA47970B1 - Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée - Google Patents
Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnéeInfo
- Publication number
- MA47970B1 MA47970B1 MA47970A MA47970A MA47970B1 MA 47970 B1 MA47970 B1 MA 47970B1 MA 47970 A MA47970 A MA 47970A MA 47970 A MA47970 A MA 47970A MA 47970 B1 MA47970 B1 MA 47970B1
- Authority
- MA
- Morocco
- Prior art keywords
- jak inhibitor
- compound
- imidazo
- inhibitor compound
- piperidine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract 3
- AIAJYBLPGVBVSS-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-imidazo[4,5-b]pyridine Chemical compound C1CCNC2=C1NC=N2 AIAJYBLPGVBVSS-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un composé de formule 1 ou un sel pharmaceutiquement acceptable de celui-ci, qui est utile en tant qu'inhibiteur de jak. L'invention concerne également des formes cristallines du composé, des compositions pharmaceutiques comprenant le composé, des procédés d'utilisation de ce dernier pour traiter des maladies sensibles à un inhibiteur de jak, et des procédés ainsi que des intermédiaires utiles pour préparer ledit composé.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492574P | 2017-05-01 | 2017-05-01 | |
| PCT/US2018/030148 WO2018204238A1 (fr) | 2017-05-01 | 2018-04-30 | Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47970B1 true MA47970B1 (fr) | 2022-03-31 |
Family
ID=62165730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47970A MA47970B1 (fr) | 2017-05-01 | 2018-04-30 | Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10493077B2 (fr) |
| EP (1) | EP3601283B1 (fr) |
| JP (1) | JP7098656B2 (fr) |
| KR (1) | KR102550225B1 (fr) |
| CN (1) | CN110573508B (fr) |
| AR (1) | AR111495A1 (fr) |
| AU (1) | AU2018261593B2 (fr) |
| BR (1) | BR112019022648A2 (fr) |
| CA (1) | CA3056283A1 (fr) |
| CL (1) | CL2019003086A1 (fr) |
| CO (1) | CO2019011809A2 (fr) |
| CY (1) | CY1125051T1 (fr) |
| DK (1) | DK3601283T3 (fr) |
| EA (1) | EA201992601A1 (fr) |
| ES (1) | ES2908756T3 (fr) |
| HR (1) | HRP20220330T1 (fr) |
| IL (1) | IL270231B2 (fr) |
| LT (1) | LT3601283T (fr) |
| MA (1) | MA47970B1 (fr) |
| MD (1) | MD3601283T2 (fr) |
| MX (1) | MX388751B (fr) |
| NZ (1) | NZ757570A (fr) |
| PH (1) | PH12019502264A1 (fr) |
| PL (1) | PL3601283T3 (fr) |
| PT (1) | PT3601283T (fr) |
| RS (1) | RS62995B1 (fr) |
| SG (1) | SG11201908604YA (fr) |
| SI (1) | SI3601283T1 (fr) |
| SM (1) | SMT202200079T1 (fr) |
| TW (1) | TWI760486B (fr) |
| UA (1) | UA124478C2 (fr) |
| WO (1) | WO2018204238A1 (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| AU2018231032B2 (en) | 2017-03-09 | 2021-08-19 | Theravance Biopharma R&D Ip, Llc | JAK inhibitors containing a 4-membered heterocyclic amide |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| KR102568333B1 (ko) | 2017-05-01 | 2023-08-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물을 사용하는 치료 방법 |
| JP7383696B2 (ja) | 2018-09-04 | 2023-11-20 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての５員～７員の複素環アミド |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| EP3837253B1 (fr) | 2018-09-04 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Procédé de préparation d'inhibiteurs de jak et intermédiaires de ceux-ci |
| SG11202103042XA (en) | 2018-10-29 | 2021-04-29 | Theravance Biopharma R&D Ip Llc | 2-azabicyclo hexane compound as jak inhibitor |
| CN113784713A (zh) | 2019-01-11 | 2021-12-10 | 纳吉斯制药股份有限公司 | 白三烯合成抑制剂 |
| WO2020173400A1 (fr) * | 2019-02-25 | 2020-09-03 | 河南迈英诺医药科技有限公司 | Composé inhibiteur de jak et son utilisation |
| PH12021552130A1 (en) | 2019-03-05 | 2022-08-31 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| EP3942045A1 (fr) | 2019-03-21 | 2022-01-26 | Onxeo | Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer |
| EP4054579A1 (fr) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| TW202144346A (zh) * | 2020-03-18 | 2021-12-01 | 四川海思科製藥有限公司 | 一種吲唑衍生物及其在醫藥上的應用 |
| CN111620868B (zh) * | 2020-05-28 | 2021-08-31 | 爱斯特（成都）生物制药股份有限公司 | 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法 |
| TW202317550A (zh) * | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025240847A1 (fr) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
| WO2026090116A2 (fr) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026090245A1 (fr) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs ras pour traiter un cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| US20120029190A1 (en) | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| SMT201700581T1 (it) | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| ES2654051T3 (es) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas |
| CN106459048A (zh) | 2014-05-14 | 2017-02-22 | 辉瑞公司 | 吡唑并吡啶类和吡唑并嘧啶类 |
| WO2016026078A1 (fr) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Composés hétérocycliques utilisés comme inhibiteurs de erk |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| PT3371185T (pt) | 2015-11-03 | 2020-12-28 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| EP3371184A1 (fr) | 2015-11-03 | 2018-09-12 | Topivert Pharma Limited | Dérivés 4,5,6,7-tétrahydro-1h-imidazo[4,5-c]pyridine et 1,4,5,6,7,8-héxahydroimidazo[4,5-d]azépine en tant qu'inhibiteurs de janus kinase |
| AU2018231032B2 (en) | 2017-03-09 | 2021-08-19 | Theravance Biopharma R&D Ip, Llc | JAK inhibitors containing a 4-membered heterocyclic amide |
| MX389014B (es) | 2017-05-01 | 2025-03-20 | Theravance Biopharma R&D Ip Llc | Formas cristalinas de un compuesto inhibidor de jak |
| KR102568333B1 (ko) | 2017-05-01 | 2023-08-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물을 사용하는 치료 방법 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
-
2018
- 2018-04-27 AR ARP180101103A patent/AR111495A1/es unknown
- 2018-04-30 WO PCT/US2018/030148 patent/WO2018204238A1/fr not_active Ceased
- 2018-04-30 MD MDE20200142T patent/MD3601283T2/ro not_active IP Right Cessation
- 2018-04-30 JP JP2019559297A patent/JP7098656B2/ja not_active Expired - Fee Related
- 2018-04-30 US US15/966,467 patent/US10493077B2/en active Active
- 2018-04-30 HR HRP20220330TT patent/HRP20220330T1/hr unknown
- 2018-04-30 BR BR112019022648A patent/BR112019022648A2/pt not_active IP Right Cessation
- 2018-04-30 ES ES18724754T patent/ES2908756T3/es active Active
- 2018-04-30 CN CN201880028413.7A patent/CN110573508B/zh not_active Expired - Fee Related
- 2018-04-30 TW TW107114647A patent/TWI760486B/zh not_active IP Right Cessation
- 2018-04-30 SI SI201830589T patent/SI3601283T1/sl unknown
- 2018-04-30 MA MA47970A patent/MA47970B1/fr unknown
- 2018-04-30 DK DK18724754.9T patent/DK3601283T3/da active
- 2018-04-30 PT PT187247549T patent/PT3601283T/pt unknown
- 2018-04-30 LT LTEPPCT/US2018/030148T patent/LT3601283T/lt unknown
- 2018-04-30 SG SG11201908604Y patent/SG11201908604YA/en unknown
- 2018-04-30 EA EA201992601A patent/EA201992601A1/ru unknown
- 2018-04-30 CA CA3056283A patent/CA3056283A1/fr active Pending
- 2018-04-30 KR KR1020197035134A patent/KR102550225B1/ko active Active
- 2018-04-30 RS RS20220238A patent/RS62995B1/sr unknown
- 2018-04-30 NZ NZ757570A patent/NZ757570A/en not_active IP Right Cessation
- 2018-04-30 SM SM20220079T patent/SMT202200079T1/it unknown
- 2018-04-30 PL PL18724754T patent/PL3601283T3/pl unknown
- 2018-04-30 AU AU2018261593A patent/AU2018261593B2/en not_active Ceased
- 2018-04-30 MX MX2019012942A patent/MX388751B/es unknown
- 2018-04-30 UA UAA201911546A patent/UA124478C2/uk unknown
- 2018-04-30 EP EP18724754.9A patent/EP3601283B1/fr active Active
-
2019
- 2019-09-30 PH PH12019502264A patent/PH12019502264A1/en unknown
- 2019-10-18 US US16/656,940 patent/US11160810B2/en not_active Expired - Fee Related
- 2019-10-24 CO CONC2019/0011809A patent/CO2019011809A2/es unknown
- 2019-10-28 CL CL2019003086A patent/CL2019003086A1/es unknown
- 2019-10-28 IL IL270231A patent/IL270231B2/en unknown
-
2021
- 2021-09-28 US US17/449,131 patent/US20220008428A1/en not_active Abandoned
-
2022
- 2022-03-09 CY CY20221100192T patent/CY1125051T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
| MA49956B1 (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
| MA51620B1 (fr) | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques | |
| EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
| MA41256B1 (fr) | Dosage spécifique de site d'un inhibiteur de btk | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| CL2021002165A1 (es) | Nuevos derivados de compuestos heterociclicos y uso de los mismos | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| MA55193B1 (fr) | Procédés de préparation d'un inhibiteur de pi3k | |
| AU2018277520A1 (en) | 6-5 fused rings as C5a inhibitors | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
| MA30523B1 (fr) | Compose tricylique et utilisation pharmaceutique de celui-ci |